期刊文献+

外源性EPO治疗肾性贫血患者相关红细胞参数研究 被引量:3

Study of Related Erythrocyte Parameters of Renal Anemia Patient Treated by Exogenous EPO
下载PDF
导出
摘要 目的 通过分析肾性贫血患者经外源性促红细胞生成素(EPO)治疗后相关血细胞参数(血红蛋白、红细胞比容、网织红细胞计数、网织红细胞生成指数等)水平及其之间的关系,为临床治疗肾性贫血提供依据.方法 肾性贫血组61例,非肾性贫血组59例,对照组64例.采用酶联免疫吸附试验(ELISA)同时检测各组EPO水平,采用Sysmex XE-2100型血细胞分析仪检测血红蛋白(HGB)、网织红细胞百分率(Ret%)、低荧光网织红细胞比率(LFR%)、中荧光网织红细胞比率(MFR%)、高荧光网织红细胞比率(HFR%)和红细胞比容(HCT).结果 同对照组相比,肾性贫血组EPO,HGB和HCT水平显著降低,差异有统计学意义(t=2.639,2.179,2.201;P均<0.05);非肾性贫血组HGB和HCT水平显著降低,EPO水平显著升高,差异有统计学意义(t=2.074,2.819,2.145;P<0.05);给予肾性贫血患者外源性EPO治疗后,治疗有效组46例,治疗无效组15例,治疗有效组HGB,RET,HFR,MFR和HCT水平升高,差异有统计学意义(t=2.112,2.132,2.160,2.029,2.159;P均<0.05),LFR差异无统计学意义(t=1.866,P>0.05);治疗无效组RET,LFR显著升高,差异有统计学意义(t=2.248,2.124;P<0.05),HGB,HFR,MFR和HCT差异无统计学意义(t=1.903,1.898,1.919,1.834;P>0.05).结论 肾性贫血患者相关红细胞参数的研究,有助于分析研究肾性贫血患者给予外源性EPO治疗后,患者骨髓红系生长情况,从而为临床医师采取相应的治疗方式改善贫血提供依据. Objective Detecting the level of erythrocyte parameters (hemoglobin, hematocrit, rcticuloeyte count, reticulocyte production index et al) of nephropathy dialysis patients,to provide the basis of correct treatment. Methods 61 cases of ne-phropathy dialysis patients,59 cases of non-nephropathy dialysis patients, 64 cases of controls were collected. The level of EPO was detected bydouble antibody sandwich principle enzyme-linked immunosorbent assay (ELISA) ,and the level of he-moglobin (HGB), reticulocyte percentage (Ret%), immature reticulocyte ratio (IRF%), low fluorescent reticulocyte ratio ( LFR% ), fluorescent reticulocyte ratio (MFR%), high fluorescent reticulocyte ratio ( HFR% ), and hematocrit (HCT) were detected by Sysmex XE-2100 type blood cell analyzer. Results Compared to control group, the levels of EPO, HGB and HCT of renal anemia group were reduced significantly (t=2. 639,2. 179,2. 201;P〈0. 05), the level of HGB, HCT of non-renal anemia group were reduced significantly (P〈0.05),the level of EPO was increased significantly (t= 2. 074,2. 819, 2. 145;P〈0. 05);Furthermore,given to patients with exogenous EPO treatment, 46 cases were effective and 15 cases were invalid. In the effective group, the levels of H GB, HFR, MFR, IRF and HCT were increased significantly (t=2.112,2. 132, 2.160,2.029,2.159 ; P〈0. 05 ), and the level of LFR showed no significant change (t = 1. 866, P〉 0.05). In the invalid group,the levels of RET and LFR were increased significantly (t=2. 248,2. 124;P〈0. 05),the levels of HGB, HFR,MFR and HCT showed no significant change (t=1. 903,1. 898,1. 919,1. 834;P〉0.05). Conclusion The EPO level and related erythrocyte parameters detection are helpful to find out bone marrow erythroid growth situation for renal anemia patients given exogenous EPO,and to provide the basis for clinical diagnosis and treatment.
作者 唐斌
机构地区 天津港口医院
出处 《现代检验医学杂志》 CAS 2013年第5期53-55,共3页 Journal of Modern Laboratory Medicine
关键词 促红细胞生成素(EPO) 肾性贫血 红细胞相关参数 erythropoietin(EPO) renal anemia red cell parameters
  • 相关文献

参考文献7

二级参考文献72

共引文献504

同被引文献26

  • 1付新欣,徐承杰.红细胞参数在慢性肾衰中的应用[J].医学检验与临床,2010(4):46-48. 被引量:1
  • 2金艳慧,王明山,郑加永,袁谦.肾性贫血中未成熟网织红细胞的变化及意义[J].实用医学杂志,2005,21(17):1951-1953. 被引量:10
  • 3Littlewood TJ, Zagari M, Pallister C, et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients [J].The Oncologist, 2003,8 (1):99 107.
  • 4Sathyanarayana P, Menon MP, Bogacheva O, et alo Erythropoietin modulation of podocalyxin and 8 pro- posed erythroblastniche[J]. Blood, 2007,110 (2) : 509- 518.
  • 5Belonje AM,Voors AA,van der Meer P,et al. Endog- enous erythropoietin and outcome in heart failure[J]. Circulation, 2010,121 (2) :245-251.
  • 6Klausen T, Christensen H, Vidiendal olsen N, et al. Human erythropoietin response to hypocapnic hypox- ia, normocapnie hypoxia, and hypocapnic normoxia [J]. Eur J Appl Physiol,1996,74(5) :475-480.
  • 7Mustaechi G, Ceccherini R, Dellach C, et al. An in- duction dose of epoetin alpha of 40000 IU daily {or three consecutive days increases and maintains he- moglobin levels in anemic cancer patients undergoing chemotherapy[J]. Ann Oncol, 2006,17 ( 11 ) :1705- 1708.
  • 8BEIRAGHDAR F, PANAHI Y, EINOLLAHI B, et al. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial[J]. Clin Lab, 2012, 58 (7-8): 737-745.
  • 9SHIBATA M, TANIGUCHI S. Iron supplementation therapy in end-stage renal disease patients on maintenance hemodialysis[J]. Cardiovasc Hematol Disord Drug Targets, 2013 , 13 (3): 237-242.
  • 10ECKHARDT A, FREIBERG MA, DE LA FUENTE J, et al. Clinical usefulness of the reticulocyte hemoglobin equivalent in chronic hemodialysis patients[J]. Rev Fac Cien Med Univ Nac Cordoba, 2011, 68 (2): 51-55.

引证文献3

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部